Parkside Scientific Inc.
Readying drug cures for deadly cancers (Prostate; Triple-Neg. Breast) and other diseases (IBD, MS) by novel epigenetic approach of turning genes "on/off".
Parkside designs and develops drugs based on pioneering epigenetic work of our Founder/CSO Ming-Ming Zhou, who continues to Chair Mount Sinai's Pharmacological Sci Dept. (30 labs). Leveraging existing multi-$MM equipment and trained scientists, Parkside directs sophisticated R&D Agmts with Zhou Lab at Mount Sinai and First Bethune Hospital (China). In-house focus on unique proprietary drug design. Efficiently outsource mundane work to CROs.